GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a $18.00 price target on the stock.

A number of other analysts have also recently commented on the stock. Alliance Global Partners assumed coverage on shares of GeoVax Labs in a research note on Monday, November 11th. They issued a “buy” rating and a $15.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $14.20.

GeoVax Labs Stock Down 2.1 %

Shares of GOVX stock opened at $1.91 on Friday. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18. The business’s fifty day simple moving average is $2.33 and its 200-day simple moving average is $2.74.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to analysts’ expectations of $1.84 million. During the same quarter last year, the business posted ($4.80) earnings per share. As a group, research analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current year.

Institutional Trading of GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC bought a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned about 0.43% of GeoVax Labs at the end of the most recent reporting period. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.